Trial Profile

A randomized, double-blind, phase 2 study evaluating explore dose-related endometrial effects of conjugated estrogens/bazedoxifene (CE/BZA) in nonhysterectomized, symptomatic (with hot flushes [HFs]) postmenopausal women

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 18 Jun 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Conjugated estrogens/bazedoxifene (Primary) ; Bazedoxifene; Conjugated estrogens; Medroxyprogesterone
Indications Menopausal syndrome
Focus Therapeutic Use

18 Jun 2019 New trial record
01 Mar 2018 Primary endpoint "Endometrial thickness on transvaginal ultrasound of Conjugated-estrogens/bazedoxifene vs Conjugated-estrogens" has been met, as reported in an article published in the Menopause

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com